1stline Study Capecitabine Administered on Continuous Way Plus Oxaliplatin&Bevacizumab Every 2weeks in Metastatic CCR.

NCT00345696 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Colorectal Cancer

Interventions

DRUG: Bevacizumab
DRUG: Capecitabine
DRUG: Oxaliplatine

Sponsor

Unidad Integral de Investigación en Oncología S.L.

Collaborators

[object Object]